The Claim
In adults with type 2 diabetes, treatment with tirzepatide results in greater reductions in proinsulin levels and proinsulin-to-insulin ratios compared to treatment with dulaglutide, indicating enhanced insulin processing and decreased endoplasmic reticulum stress in pancreatic beta cells.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with type 2 diabetes, the drug tirzepatide lowers proinsulin and the ratio of proinsulin to insulin more than dulaglutide, suggesting more efficient insulin production and less stress in the insulin-producing cells of the pancreas.
See the scientific wording
In adults with type 2 diabetes, tirzepatide reduces proinsulin levels and proinsulin-to-insulin ratios more than dulaglutide, indicating improved insulin processing and reduced endoplasmic reticulum stress in pancreatic beta cells.
Tirzepatide activates two specific receptors on insulin-producing cells in the pancreas, which helps these cells work more efficiently and reduces the strain they feel when making insulin. This lets them convert the raw version of insulin into the final, usable form more cleanly, so less faulty insulin is released into the blood.
What the research says
1 studyTirzepatide helped the pancreas make insulin more cleanly than dulaglutide, releasing fewer faulty insulin pieces, which means the insulin-producing cells were under less stress.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.